Send to

Choose Destination
AIDS. 2013 Sep 24;27(15):2485-8. doi: 10.1097/QAD.0b013e328363b1f9.

Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C.

Author information

aMRC Centre for Virus Research, University of Glasgow, Glasgow bDepartment of Virology, Imperial College NHS Trust cDepartment of Medicine, Imperial College London, London, UK.


NS3 protease inhibitors are set to improve sustained virological response rates in HIV-positive patients with hepatitis C. We measured the prevalence of natural resistance polymorphisms in 38 acutely infected treatment-naive patients using direct and deep sequencing. Twenty six percent of patients (10/38) had a majority variant resistance mutation (in order of frequency; Q80K - 16%, V36M - 5%, T54S - 3%, V55A - 3%, and D168A - 3%). Low-frequency mutations were detected in all samples. Further studies are required to determine threshold levels associated with treatment failure.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center